4.6 Article

Combination of selol nanocapsules and magnetic hyperthermia hinders breast tumor growth in aged mice after a short-time treatment

Journal

NANOTECHNOLOGY
Volume 33, Issue 20, Pages -

Publisher

IOP Publishing Ltd
DOI: 10.1088/1361-6528/ac504c

Keywords

selol-loaded PLGA-nanocapsule; Ehrlich tumor; maghemite nanoparticles; elderly mice; magnetic hyperthermia; mathematical modeling

Funding

  1. Coordination for the Improvement of Higher Education Personnel (CAPES)
  2. Brazilian National Council for Technological and Scientific Development (CNPq)
  3. Foundation to Support Research in the Federal District (FAPDF)
  4. National Institute of Science and Technology in Nanobiotechnology (INCT-Nanobiotecnologia)
  5. Center for Nanoscience and Nanobiotechnology of the University of Brasilia (CNANO-UnB)
  6. University of Brasilia (DPP-UnB)

Ask authors/readers for more resources

The short-term treatment with reduced dosages of NcSel-loaded PLGA nanocapsules combined with magnetic hyperthermia (MHT) was evaluated in aged Erhlich tumor-bearing mice. The study found that the combined therapy was able to inhibit primary tumor growth and achieve complete tumor remission without metastasis and significant adverse effects. This combination may be an effective and safe alternative for cancer control in aged patients.
Short time treatment with reduced dosages of selol-loaded PLGA nanocapsules (NcSel) combined with magnetic hyperthermia (MHT) is evaluated in aged Erhlich tumor-bearing mice. Clinical, hematological, biochemical, genotoxic and histopathological parameters are assessed during 7 d treatment with NcSel and MHT, separately or combined. The time evolution of the tumor volume is successfully modeled using the logistic mathematical model. The combined therapy comprising NcSel and MHT is able to hinder primary tumor growth and a case of complete tumor remission is recorded. Moreover, no metastasis was diagnosed and the adverse effects are negligible. NcSel plus MHT may represent an effective and safe alternative to cancer control in aged patients. Future clinical trials are encouraged.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available